MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30429468.
- Also identified by DOI 10.1038/s41467-018-07250-6 and PMC identifier 6235838.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cell-based drug delivery systems have shown promising capability for tumor-targeted therapy owing to the intrinsic tumor-homing and drug-carrying property of some living cells. However, imaging tracking of their migration and bio-effects is urgently needed for clinical application, especially for glioma. Here, we report the inflammation-activatable engineered neutrophils by internalizing doxorubicin-loaded magnetic mesoporous silica nanoparticles (ND-MMSNs) which can provide the potential for magnetic resonance (MR) imaging tracking of the drug-loaded cells to actively target inflamed brain tumor after surgical resection of primary tumor. The phagocytized D-MMSNs possess high drug loading efficiency and do not affect the host neutrophils' viability, thus remarkably improving intratumoral drug concentration and delaying relapse of surgically treated glioma. Our study offers a new strategy in targeted cancer theranostics through combining the merits of living cells and nanoparticle carriers.
Medical subject headings
- Antibiotics, Antineoplastic
- Brain Neoplasms
- Doxorubicin
- Drug Carriers
- Glioma
- Nanoparticles
- Neutrophils